@article{53ee17172ae345f0976930f727334555,
title = "Could Neprilysin Be Already Inhibited by BNP in the LIFE Trial? - Reply",
author = "Mann, \{Douglas L.\} and Hernandez, \{Adrian F.\} and Eugene Braunwald",
note = "Funding Information: Conflict of Interest Disclosures: Dr Mann has received personal fees from Novo Nordisk and Bristol Myers Squibb. Dr Hernandez has received grants from Novartis, Amgen, Boehringer Ingelheim, Merck, and American Regent as well as personal fees from AstraZeneca, Bayer, Boston Scientific, and Cytokinetics. Dr Braunwald has received grants from AstraZeneca, Daiichi Sankyo, Merck, and Novartis through his institution, personal fees from Amgen, Boehringer Ingelheim/Lilly, Cardurion, Bristol Myers Squibb, Novo Nordisk, and Verve.",
year = "2022",
month = jun,
doi = "10.1001/jamacardio.2022.0787",
language = "English",
volume = "7",
pages = "657--658",
journal = "JAMA Cardiology",
issn = "2380-6583",
number = "6",
}